mRNA Platforms and Vaccine Iteration Speed

mRNA平台与疫苗迭代速度

课文音频

可先听下面的整段朗读；需要逐句点读时，请打开阅读器，体验会更顺手。

课文

mRNA vaccines don’t contain live virus—they deliver genetic instructions for making just one harmless viral protein.

mRNA疫苗不含活病毒，只提供合成一种无害病毒蛋白的遗传指令。
Once the platform is validated, swapping the mRNA sequence lets scientists build a new vaccine in weeks, not years.

平台一旦验证成功，只需更换mRNA序列，科学家几周内即可研发出新疫苗，无需数年。
During the Omicron surge, updated boosters entered clinical trials just 48 days after the variant’s genome was shared.

奥密克戎流行期间，更新版加强针在该变异株基因组公布后仅48天就进入临床试验。
This speed relies on standardized lipid nanoparticles that safely carry any mRNA payload into human cells.

这种速度依赖于标准化脂质纳米颗粒，可安全将任意mRNA递送至人体细胞。
Manufacturing doesn’t require growing viruses in eggs or bioreactors, cutting both time and contamination risk.

生产无需在鸡蛋或生物反应器中培养病毒，大幅缩短周期并降低污染风险。
Regulators now approve updates based on lab data alone—no need to repeat large-scale efficacy trials each time.

监管机构如今仅凭实验室数据即可批准更新，无需每次重复大规模有效性试验。
Future flu shots may refresh annually like software, matching circulating strains with precision and agility.

未来流感疫苗或像软件一样每年升级，精准、敏捷地匹配流行毒株。
The platform’s flexibility makes it ideal not only for infectious disease but also for personalized cancer vaccines.

该平台的灵活性使其不仅适用于传染病，也适合个性化癌症疫苗。